

Press Release

Medicines for Europe delegation leads on manufacturing, sustainability and access at CPHI congress

Milan, 09 October 2024

A delegation of Medicines for Europe leaders is representing the off-patent medicines industry at this year's CPHI conference in Milan.

On **critical medicines manufacturing**, Medicines for Europe supports an ambitious EU **Critical Medicines Act** in the **first 100 days after of the European Commission taking office**. The Act would ensure equitable access to high-quality, safe, effective and affordable critical medicines, 90% of which are off-patent. Our members are dedicated to co-investing in EU manufacturing of critical medicines and Active Pharmaceutical Ingredients (APIs) as highlighted in the panel co-hosted by DG HERA entitled "Safeguarding the Future of Medicines". The Act must address the economic root causes of medicine shortages, stress EU solidarity and include manufacturing incentives fit for the off-patent sector by adapting the legal definition of innovation as highlighted in the recent Draghi report.

On **sustainability**, the members of Medicines for Europe are underlining their commitment to the environment and the climate alongside better access to medicines. This is delivered with decarbonization and investment into energy and water efficiency and waste management. Unfortunately, there are some counterproductive EU laws coming up that undermine the efforts of the industry to combine environment and access, like the Urban Waste Water Treatment Directive. Medicines for Europe will engage with other stakeholders to align access and environmental goals based on one health.

On **equitable and timely access**, we will share how **biosimilar medicines - a scientific, regulatory and legal invention made in Europe - available** to date in the EU have improved access to key biological therapies for patients with positive clinical experience of over 5.8 billion patient treatment days. Looking to the future, the connection between access to the next generation of biosimilar medicines, involving new biotechnological platforms (e.g. Antibody Drug conjugates, Cell & Gene), and the need for a strong competitive EU biotech industrial ecosystem and policy framework will also be illustrated.

Meet Medicines for Europe's experts at this year CPHI Milan

	<p>Elisabeth Stampa Board member, Medichem S.A & President of Medicines for Europe.</p> <p> The Future of Pharma Manufacturing</p>		<p>Rebecca Guntern CCO Sandoz</p> <p> Safeguarding the Future of Medicine</p>
	<p>Markus Sieger CEO Polpharma Group B.V.</p> <p> Safeguarding the Future of Medicine</p> <p> Safeguarding the Supply Chain from Ingredient Shortage</p>		<p>Julie Marechal-Jamil Director Biosimilars Policy & Science, Medicines for Europe</p> <p> Improving Patient Access with Biosimilars</p>
	<p>Philippe Drechsle Vice President EU Portfolio, Teva</p> <p> Safeguarding the Future of Medicine</p>		<p>Ines Windisch Head of Communications, Corporate Affairs & Sustainability, Zentiva</p> <p> Solutions to Sustainable Manufacturing - Green Facilities and Chemistry</p>

Resource hub

The policy track at CPHI Milan 2024 can be accessed at <https://www.cphi.com/europe/en/whats-on/agenda/conference-agenda.html>

The Medicines for Europe proposal for a Critical Medicines Act can be accessed at: <https://www.medicinesforeurope.com/wp-content/uploads/2024/09/Critical-Medicines-Act-delivering-a-secure-supply-of-critical-medicines-and-active-pharmaceutical-ingredients-in-Europe.pdf>

Critical Medicines Act Infographic: <https://www.medicinesforeurope.com/wp-content/uploads/2024/04/European-Medicines-Security-26-9-2024.pdf>

Medicines for Europe

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe, and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing

to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information, please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU.